Home:
Educational
Supplement: Section 4
SELECT PUBLICATIONS
Albain K. Overall
survival after cyclophosphamide, adriamycin, 5-FU and tamoxifen
(CAFT) is superior to T alone in post-menopausal, receptor(+), node(+)
breast cancer: New findings from phase III Southwest Oncology Group
Intergroup Trial S8814 (INT-0100). Proc ASCO 2001;Abstract
94.
Baum M et al.
Management of premenopausal women with early breast cancer: Is
there a role for goserelin? Proc ASCO 2001; Abstract
103.
Boccardo F
et al. Cyclophosphamide, methotrexate and fluorouracil versus
tamoxifen plus ovarian suppression as adjuvant treatment of estrogen
receptor-positive pre-/perimenopausal breast cancer patients: Results
of the Italian Breast Cancer Adjuvant Study Group 02 randomized
trial. J Clin Oncol 2000;18:2718-27. Abstract
Buchholz TA
et al. Impact of systemic treatment on local control for patients
with lymph node-negative breast cancer treated with breast-conservation
therapy. J Clin Oncol 2001;19(8):2240-6. Abstract
Cauley JA et
al. Continued breast cancer risk reduction in postmenopausal
women treated with raloxifene: 4-year results from the MORE trial.
Multiple outcomes of raloxifene evaluation. Breast Cancer
Res Treat 2001;65(2):125-34. Abstract
Cheung KL et
al. The combined use of goserelin and anastrozole as second-line
endocrine therapy in premenopausal women with advanced breast cancer
a study of its clinical and endocrine effects. Proc
ASCO 2001;Abstract
1937.
Chlebowski RT
et al. American Society of Clinical Oncology technology assessment
on breast cancer risk reduction strategies: Tamoxifen and raloxifene.
J Clin Oncol 1999;17(6):1939-55. Abstract
Davidson N
et al. Effect of chemohormonal therapy in premenopausal, node
(+), receptor (+) breast cancer: An Eastern Cooperative Oncology
Group phase III Intergroup trial (E5188, INT-0101). Proc
ASCO 1999;Abstract
249A, 67A.
Day et al. Health-related
quality of life and tamoxifen in breast cancer prevention: A report
from the National Surgical Adjuvant Breast and Bowel Project P-1
Study. J Clin Oncol 1999;17(9):2659-69. Abstract
de Haes H et
al. Early benefits in quality of life (QoL) observed in zoladex-treated
versus CMF-treated pre-/perimenopausal patients with node-positive
early breast cancer. Proc ASCO 2001; Abstract
138.
Demissie S et
al. Adjuvant tamoxifen: Predictors of use, side effects and discontinuation
in older women. J Clin Oncol 2001;19:322-8. Abstract
Fallowfield
L et al. Tamoxifen for the prevention of breast cancer: Psychosocial
impact on women participating in two randomized controlled trials.
J Clin Oncol 2001;19:1885-92. Abstract
Fisher B et
al. Five versus more than five years of tamoxifen for lymph node-negative
breast cancer: Updated findings from the National Surgical Adjuvant
Breast and Bowel Project B-14 randomized trial. J Natl Cancer
Inst 2001;93(9):684-90. Abstract
Fisher B et
al. Prognosis and treatment of patients with breast tumors of
one centimeter or less and negative axillary lymph nodes. J
Natl Cancer Inst 2001;93(2):112-20. Abstract
Fisher B et
al. Tamoxifen for prevention of breast cancer: Report of the
National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst 1998;90(18):1371-88. Abstract
Forward D et
al. Combined use of goserelin (Zoladex) and anastrozole (Arimidex)
in premenopausal women with metastatic breast cancer (MBC). Proc
ASCO 2000; Abstract
582.
Gail MH et al.
Weighing the risks and benefits of tamoxifen treatment for preventing
breast cancer. J Natl Cancer Inst 1999;91(21):1829-46.
Abstract
Ganz PA et
al. Impact of different adjuvant therapy strategies on quality
of life in breast cancer survivors. Recent Results Cancer
Res 1998;152:396-411. Abstract
Henderson IC.
Ovarian ablation comes around again. Breast Diseases:
A Year Book Quarterly 2000;11(2):117-120. No Abstract Available
Hoffken K,
Kath R. The role of LH-RH analogues in the adjuvant and palliative
treatment of breast cancer. Recent Results Cancer Res 2000;153:61-70.
Abstract
Houghton J
et al. The ZIPP trial of adjuvant zoladex in premenopausal patients
with early breast cancer: An update at five years. Proc ASCO
2000;Abstract
359.
Ingle JN et
al. Combination hormonal therapy involving aromatase inhibitors
in the management of women with breast cancer. Endocr Relat
Cancer 1999;6:265-9. Full
Text
Jakesz R. Comparison
of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal
stage I and II hormone-responsive breast cancer patients: Four-year
results of Austrian Breast Cancer Study Group (ABCSG) Trial 5.
Proc ASCO 1999;Abstract
250.
Li CI et al.
Tamoxifen therapy for primary breast cancer and risk of contralateral
breast cancer. J Natl Cancer Inst 2001;93(13):1008-13.
Abstract
Michaud LB,
Buzdar AU. Complete estrogen blockade for the treatment of metastatic
and early stage breast cancer. Drugs Aging. 2000;16:261-71.
Abstract
Nystedt M et
al. Randomized trial of adjuvant tamoxifen and/or goserelin in
premenopausal breast cancer self-rated physiological effects
and symptoms. Acta Oncol 2000;39(8):959-68. Abstract
O'Reagan RM
et al. Effect of raloxifene after tamoxifen on breast and endometrial
cancer growth. Proc ASCO 2001;Abstract
95.
O'Regan RM,
Jordan VC. Tamoxifen to raloxifene and beyond. Semin Oncol
2001;28(3):260-73. Abstract
Rockhill B
et al. Validation of the Gail et al model of breast cancer risk
prediction and implications for chemoprevention. J Natl Cancer
Inst 2001;93(5):358-66. Abstract
Rutqvist LE.
Zoladex ® and tamoxifen as adjuvant therapy in premenopausal
breast cancer: A randomised trial by the Cancer Research Campaign
(C. R. C.) Breast Cancer Trials Group, the Stockholm Breast Cancer
Study Group, The South-East Sweden Breast Cancer Group & the
Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.
I. V. I. O). Proc ASCO 1999;Abstract
251. Stewart
HJ et al. Scottish adjuvant tamoxifen trial: A randomized study
updated to 15 years. J Natl Cancer Inst 2001;93(6):456-62.
Abstract
Sverrisdottir
A et al. Bone mineral density in premenopausal patients in a
randomized trial of adjuvant endocrine therapy (ZIPP-TRIAL).
Proc ASCO 2001;Abstract
96.
Wickerham DL,
Tan-Chiu E. Breast cancer chemoprevention: Current status and
future directions. Semin Oncol 2001;28(3):253-9. Abstract
Top
Additional
Sections:
1 | 2
| 3 | 4
| 5 | 6
| 7 | 8
| 9 | 10
| 11 | 12
|
|